SALT LAKE CITY— Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients ...

Clinical Associate Professor of Medicine, Department of Internal Medicine and Gastroenterology, MCP Hahnemann University, Philadelphia, Pennsylvania; Chief, Division of Internal Medicine, Department ...

In about 5–10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Surgery precedes biologics but comes after saline irrigations and topical intranasal corticosteroids in a new treatment algorithm for US clinicians treating patients who have chronic rhinosinusitis ...

Please provide your email address to receive an email when new articles are posted on . Extended use of omalizumab up to 1 year showed efficacy for the treatment of uncontrolled chronic rhinosinusitis ...

Mepolizumab was found to reduce nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps regardless of the presence of potentially exacerbating comorbidities.

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and safety ...

YARDLEY, Pa., June 2, 2021 /PRNewswire/ — Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy ...

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...